Screener
Net Income at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed July 28, 2026.
- Filed
- Jul 28, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-087545
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Other income, net | 3,951 | 2,717 | 7,365 | 5,010 |
| Income before income taxes | 31,145 | 22,877 | 63,826 | 38,442 |
| Provision for income taxes | (5,713) | (5,045) | (15,802) | (12,071) |
| Net income | $25,432 | $17,832 | $48,024 | $26,371 |
| Net income per share attributable to ordinary shareholders—basic | $0.33 | $0.24 | $0.62 | $0.36 |
| Net income per share attributable to ordinary shareholders—diluted | $0.30 | $0.23 | $0.58 | $0.34 |
| Weighted average ordinary shares outstanding—basic | 77,577,675 | 73,438,530 | 77,050,036 | 73,041,920 |
| Weighted average ordinary shares outstanding—diluted | 83,398,051 | 77,942,082 | 82,902,904 | 76,984,393 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Kiniksa Pharmaceuticals International, plc's net income?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported net income of $25.43M in Q2 2026.
- How has Kiniksa Pharmaceuticals International, plc's net income changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's net income increased by 42.6% year-over-year, from $17.83M to $25.43M.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's net income?
- Over 4 years (2021 to 2025), Kiniksa Pharmaceuticals International, plc's net income has grown at a -21.8% compound annual growth rate (CAGR), from -$157.92M to $59.01M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Kiniksa Pharmaceuticals International, plc's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude